share_log

10-Q: Q1 2024 Earnings Report

10-Q: Q1 2024 Earnings Report

10-Q:2024财年一季报
美股SEC公告 ·  05/15 17:08

Moomoo AI 已提取核心信息

180 Life Sciences Corp. reported financial results for the quarter ended March 31, 2024, with a net loss of $1,069,744, a decrease from the net loss of $4,762,078 for the same period in 2023. Research and development expenses decreased by 37% to $365,186, while general and administrative expenses saw a significant reduction of 61% to $1,556,740. The company also reported other income of $1,022,724, primarily due to the forgiveness of certain R&D program-related liabilities. Despite these changes, the company continues to face challenges, including non-compliance with Nasdaq's continued listing standards regarding minimum stockholders' equity, which has resulted in a delisting determination letter from Nasdaq. The company is actively seeking to regain compliance and is considering strategic alternatives to maximize shareholder value. Future plans include continued development of...Show More
180 Life Sciences Corp. reported financial results for the quarter ended March 31, 2024, with a net loss of $1,069,744, a decrease from the net loss of $4,762,078 for the same period in 2023. Research and development expenses decreased by 37% to $365,186, while general and administrative expenses saw a significant reduction of 61% to $1,556,740. The company also reported other income of $1,022,724, primarily due to the forgiveness of certain R&D program-related liabilities. Despite these changes, the company continues to face challenges, including non-compliance with Nasdaq's continued listing standards regarding minimum stockholders' equity, which has resulted in a delisting determination letter from Nasdaq. The company is actively seeking to regain compliance and is considering strategic alternatives to maximize shareholder value. Future plans include continued development of therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases, with a focus on three product development platforms: fibrosis and anti-TNF, CBD derivatives, and α7nAChR. However, due to resource constraints, research and development activities in the SCA and anti-TNF platforms have slowed, and the α7nAChR platform has been suspended.
180 Life Sciences Corp于2024年3月31日公布了财务报告,净亏损为1,069,744美元,与2023年同期净亏损的4,762,078美元相比有所下降。研发费用减少了37%,至365,186美元,而一般和管理费用则显著减少了61%,至1,556,740美元。该公司还报告了1,022,724美元的其他收入,主要归因于某些与研发项目相关的负债的豁免。尽管发生了这些变化,该公司仍然面临着挑战,包括未遵守纳斯达克关于最低股东权益的继续上市标准,这导致了纳斯达克的摘牌决定通知书。该公司正在积极寻求恢复合规,并考虑战略性的替代方案以最大化股东价值。未来的计划包括继续开发治疗慢性疼痛、炎症、纤维化和其他炎症性疾病的治疗方法,专注于三个产品开发平台:纤维化和抗TNF、CBD衍生物和α7nAChR。然而,由于资源限制,SCA和抗TNF平台的研发活动放缓,而α7nAChR平台已经暂停。
180 Life Sciences Corp于2024年3月31日公布了财务报告,净亏损为1,069,744美元,与2023年同期净亏损的4,762,078美元相比有所下降。研发费用减少了37%,至365,186美元,而一般和管理费用则显著减少了61%,至1,556,740美元。该公司还报告了1,022,724美元的其他收入,主要归因于某些与研发项目相关的负债的豁免。尽管发生了这些变化,该公司仍然面临着挑战,包括未遵守纳斯达克关于最低股东权益的继续上市标准,这导致了纳斯达克的摘牌决定通知书。该公司正在积极寻求恢复合规,并考虑战略性的替代方案以最大化股东价值。未来的计划包括继续开发治疗慢性疼痛、炎症、纤维化和其他炎症性疾病的治疗方法,专注于三个产品开发平台:纤维化和抗TNF、CBD衍生物和α7nAChR。然而,由于资源限制,SCA和抗TNF平台的研发活动放缓,而α7nAChR平台已经暂停。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息